Lilly's Cyramza scores in targeted lung cancer—but major competition awaits

12th March 2019 Uncategorised 0

Eli Lilly has new data that could help expand Cyramza’s lung cancer footprint. But if it does win approval to treat EGFR-mutated tumors, it’ll face a tough field of competitors.

More: Lilly's Cyramza scores in targeted lung cancer—but major competition awaits
Source: fierce